[144] Guardant Health, Inc. SEC Filing
This Form 144 notice records a proposed sale of 100 shares of Guardant Health, Inc. common stock through Charles Schwab & Co., Inc., with an aggregate market value of $6,584 and an approximate sale date of 09/02/2025. The filer reports acquiring the shares through restricted stock lapses: 34 shares on 06/12/2025 and 66 shares on 07/04/2025, both listed as equity compensation.
The filing also discloses sales by the same person within the past three months: 100 shares sold on 06/02/2025 for $4,166 and 3,337 shares sold on 06/13/2025 for $157,573. The notice includes a representation that the seller is not aware of undisclosed material adverse information about the issuer.
Questa comunicazione Form 144 segnala una proposta di vendita di 100 azioni ordinarie di Guardant Health, Inc. tramite Charles Schwab & Co., Inc., con un valore di mercato complessivo di $6.584 e una data di vendita approssimativa del 02/09/2025. Il dichiarante riferisce di aver acquisito le azioni tramite l鈥檈stinzione di restrizioni su azioni: 34 azioni il 12/06/2025 e 66 azioni il 04/07/2025, entrambe indicate come compenso azionario.
Il deposito riporta inoltre vendite della stessa persona negli ultimi tre mesi: 100 azioni vendute il 02/06/2025 per $4.166 e 3.337 azioni vendute il 13/06/2025 per $157.573. L鈥檃vviso include la dichiarazione che il venditore non 猫 a conoscenza di informazioni negative rilevanti non divulgate sull鈥檈mittente.
Este aviso del Formulario 144 registra una propuesta de venta de 100 acciones ordinarias de Guardant Health, Inc. a trav茅s de Charles Schwab & Co., Inc., con un valor de mercado agregado de $6.584 y una fecha aproximada de venta del 02/09/2025. El declarante informa haber adquirido las acciones por la liberaci贸n de restricciones sobre acciones: 34 acciones el 12/06/2025 y 66 acciones el 04/07/2025, ambas registradas como compensaci贸n en acciones.
La presentaci贸n tambi茅n divulga ventas de la misma persona en los 煤ltimos tres meses: 100 acciones vendidas el 02/06/2025 por $4.166 y 3.337 acciones vendidas el 13/06/2025 por $157.573. El aviso incluye la declaraci贸n de que el vendedor no tiene conocimiento de informaci贸n material adversa no divulgada sobre el emisor.
鞚� Form 144 韱奠靹湹鐢 Charles Schwab & Co., Inc.毳� 韱淀暣 Guardant Health, Inc. 氤错喌欤� 100欤�毳� 毵る弰頃� 鞓堨爼鞛勳潉 旮半頃橂┌, 齑� 鞁滉皜 $6,584 氚� 鞓堨儊 毵る弰鞚� 2025/09/02毳� 旮办灛頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖鞛惖鐢 鞝滍暅欤� 頃挫牅搿� 欤检嫕鞚� 旆摑頄堧嫟瓿� 氤搓碃頃橃榾鞙茧┌, 34欤�电� 2025/06/12, 66欤�电� 2025/07/04鞐� 臧侁皝 旆摑霅橃棃瓿� 霊� 雼� 欤检嫕 氤挫儊鞙茧 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 鞝滌稖靹滌棎电� 霃欖澕鞚胳澊 斓滉芳 3臧滌洈 雮挫棎 鞁れ嫓頃� 毵る弰霃� 瓿店皽霅橃柎 鞛堨姷雼堧嫟: 2025/06/02鞐� 100欤� 毵る弰, $4,166 氚� 2025/06/13鞐� 3,337欤� 毵る弰, $157,573. 韱奠靹滌棎电� 毵る弰鞚胳澊 氚滍枆須岇偓鞐� 甏�頃� 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞚胳頃橁碃 鞛堨 鞎婋嫟电� 歆勳垹霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Cet avis Formulaire 144 enregistre une proposition de vente de 100 actions ordinaires de Guardant Health, Inc. via Charles Schwab & Co., Inc., d鈥檜n valeur de march茅 totale de $6鈥�584 et d鈥檜ne date de vente approximative au 02/09/2025. Le d茅clarant indique avoir acquis les actions par lev茅e de restrictions sur titres : 34 actions le 12/06/2025 et 66 actions le 04/07/2025, toutes deux class茅es comme r茅mun茅ration en actions.
Le d茅p么t divulgue 茅galement des ventes par la m锚me personne au cours des trois derniers mois : 100 actions vendues le 02/06/2025 pour $4鈥�166 et 3鈥�337 actions vendues le 13/06/2025 pour $157鈥�573. L鈥檃vis inclut la d茅claration que le vendeur n鈥檃 pas connaissance d鈥檌nformations d茅favorables importantes non divulgu茅es concernant l鈥櫭﹎etteur.
Diese Form-144-Mitteilung verzeichnet einen geplanten Verkauf von 100 Aktien der Stammaktien von Guardant Health, Inc. 眉ber Charles Schwab & Co., Inc., mit einem gesamten Marktwert von $6.584 und einem ungef盲hren Verkaufstermin am 02.09.2025. Der Meldende gibt an, die Aktien durch das Erl枚schen von Beschr盲nkungen erhalten zu haben: 34 Aktien am 12.06.2025 und 66 Aktien am 04.07.2025, beide als 础办迟颈别苍惫别谤驳眉迟耻苍驳 ausgewiesen.
Die Einreichung offenbart au脽erdem Verk盲ufe derselben Person innerhalb der letzten drei Monate: 100 Aktien verkauft am 02.06.2025 f眉r $4.166 und 3.337 Aktien verkauft am 13.06.2025 f眉r $157.573. Die Mitteilung enth盲lt die Erkl盲rung, dass der Verk盲ufer keine Kenntnisse 眉ber nicht offengelegte wesentliche nachteilige Informationen 眉ber den Emittenten hat.
- Transparent disclosure of proposed sale details including broker, share count, and aggregate market value
- Acquisition method clarified as restricted stock lapses with dates and amounts provided
- Past three-month sales disclosed, enabling investors to track recent insider dispositions
- Recent substantial sale on 06/13/2025 of 3,337 shares for $157,573 could be viewed as notable insider liquidity
Insights
TL;DR Routine insider transaction notice showing recent restricted stock vesting and planned small sale; prior larger sale in June is disclosed.
The filing documents standard Rule 144 procedural steps for an insider or affiliate planning to sell recently vested restricted shares. The proposed transaction is small in this notice (100 shares, $6,584 market value) and arises from equity compensation events dated 06/12/2025 and 07/04/2025. Notably, the filer reported meaningful prior sales in June totaling 3,437 shares for $161,739 across two dispositions, which are disclosed as completed transactions. From a compliance and market-disclosure perspective, the form fulfills Rule 144 notice requirements and provides transparent tracking of recent insider liquidity events.
TL;DR Disclosure aligns with Rule 144 obligations; raises standard governance considerations about insider selling cadence.
The form includes acquisition details (restricted stock lapses) and identifies the broker and planned sale date, meeting regulatory disclosure norms. The seller also certified absence of undisclosed material adverse information. While the document itself is procedural, the sequence of a larger sale on 06/13/2025 followed by additional sales and a planned sale may be of interest to governance reviewers assessing insider trading policies and trading-plan usage. The filing does not state any trading-plan dates or indicate reliance on Rule 10b5-1.
Questa comunicazione Form 144 segnala una proposta di vendita di 100 azioni ordinarie di Guardant Health, Inc. tramite Charles Schwab & Co., Inc., con un valore di mercato complessivo di $6.584 e una data di vendita approssimativa del 02/09/2025. Il dichiarante riferisce di aver acquisito le azioni tramite l鈥檈stinzione di restrizioni su azioni: 34 azioni il 12/06/2025 e 66 azioni il 04/07/2025, entrambe indicate come compenso azionario.
Il deposito riporta inoltre vendite della stessa persona negli ultimi tre mesi: 100 azioni vendute il 02/06/2025 per $4.166 e 3.337 azioni vendute il 13/06/2025 per $157.573. L鈥檃vviso include la dichiarazione che il venditore non 猫 a conoscenza di informazioni negative rilevanti non divulgate sull鈥檈mittente.
Este aviso del Formulario 144 registra una propuesta de venta de 100 acciones ordinarias de Guardant Health, Inc. a trav茅s de Charles Schwab & Co., Inc., con un valor de mercado agregado de $6.584 y una fecha aproximada de venta del 02/09/2025. El declarante informa haber adquirido las acciones por la liberaci贸n de restricciones sobre acciones: 34 acciones el 12/06/2025 y 66 acciones el 04/07/2025, ambas registradas como compensaci贸n en acciones.
La presentaci贸n tambi茅n divulga ventas de la misma persona en los 煤ltimos tres meses: 100 acciones vendidas el 02/06/2025 por $4.166 y 3.337 acciones vendidas el 13/06/2025 por $157.573. El aviso incluye la declaraci贸n de que el vendedor no tiene conocimiento de informaci贸n material adversa no divulgada sobre el emisor.
鞚� Form 144 韱奠靹湹鐢 Charles Schwab & Co., Inc.毳� 韱淀暣 Guardant Health, Inc. 氤错喌欤� 100欤�毳� 毵る弰頃� 鞓堨爼鞛勳潉 旮半頃橂┌, 齑� 鞁滉皜 $6,584 氚� 鞓堨儊 毵る弰鞚� 2025/09/02毳� 旮办灛頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖鞛惖鐢 鞝滍暅欤� 頃挫牅搿� 欤检嫕鞚� 旆摑頄堧嫟瓿� 氤搓碃頃橃榾鞙茧┌, 34欤�电� 2025/06/12, 66欤�电� 2025/07/04鞐� 臧侁皝 旆摑霅橃棃瓿� 霊� 雼� 欤检嫕 氤挫儊鞙茧 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 鞝滌稖靹滌棎电� 霃欖澕鞚胳澊 斓滉芳 3臧滌洈 雮挫棎 鞁れ嫓頃� 毵る弰霃� 瓿店皽霅橃柎 鞛堨姷雼堧嫟: 2025/06/02鞐� 100欤� 毵る弰, $4,166 氚� 2025/06/13鞐� 3,337欤� 毵る弰, $157,573. 韱奠靹滌棎电� 毵る弰鞚胳澊 氚滍枆須岇偓鞐� 甏�頃� 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞚胳頃橁碃 鞛堨 鞎婋嫟电� 歆勳垹霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Cet avis Formulaire 144 enregistre une proposition de vente de 100 actions ordinaires de Guardant Health, Inc. via Charles Schwab & Co., Inc., d鈥檜n valeur de march茅 totale de $6鈥�584 et d鈥檜ne date de vente approximative au 02/09/2025. Le d茅clarant indique avoir acquis les actions par lev茅e de restrictions sur titres : 34 actions le 12/06/2025 et 66 actions le 04/07/2025, toutes deux class茅es comme r茅mun茅ration en actions.
Le d茅p么t divulgue 茅galement des ventes par la m锚me personne au cours des trois derniers mois : 100 actions vendues le 02/06/2025 pour $4鈥�166 et 3鈥�337 actions vendues le 13/06/2025 pour $157鈥�573. L鈥檃vis inclut la d茅claration que le vendeur n鈥檃 pas connaissance d鈥檌nformations d茅favorables importantes non divulgu茅es concernant l鈥櫭﹎etteur.
Diese Form-144-Mitteilung verzeichnet einen geplanten Verkauf von 100 Aktien der Stammaktien von Guardant Health, Inc. 眉ber Charles Schwab & Co., Inc., mit einem gesamten Marktwert von $6.584 und einem ungef盲hren Verkaufstermin am 02.09.2025. Der Meldende gibt an, die Aktien durch das Erl枚schen von Beschr盲nkungen erhalten zu haben: 34 Aktien am 12.06.2025 und 66 Aktien am 04.07.2025, beide als 础办迟颈别苍惫别谤驳眉迟耻苍驳 ausgewiesen.
Die Einreichung offenbart au脽erdem Verk盲ufe derselben Person innerhalb der letzten drei Monate: 100 Aktien verkauft am 02.06.2025 f眉r $4.166 und 3.337 Aktien verkauft am 13.06.2025 f眉r $157.573. Die Mitteilung enth盲lt die Erkl盲rung, dass der Verk盲ufer keine Kenntnisse 眉ber nicht offengelegte wesentliche nachteilige Informationen 眉ber den Emittenten hat.
FAQ
What does this Form 144 filing for Guardant Health (GH) report?
When were the shares acquired that are being sold under this Form 144?
Were there any insider sales by the same person recently?
Which broker is handling the proposed sale?
Does the filing state reliance on a Rule 10b5-1 trading plan?
